Dr. Amaia Lujambio's research group studies mechanisms of liver cancer initiation and liver cancer maintenance. In particular, we are interested in how genetic alterations in cancer cells contribute to tumorigenesis, alter treatment response, and create vulnerabilities that may be targeted therapeutically. In particular, we are interested in understanding how genetic alterations in liver cancer cells affect mechanisms of immune escape and response to immunotherapies. Our research interests involve the establishment of in vitro and in vivo systems for the study of liver cancer, as well as the rational use of shRNA and CRISPR libraries to identify drug targets for the disease. We utilize sophisticated mouse models for cancer, RNAi and CRISPR technologies, valuable human cancer samples, and genetic and epigenetic profiling as key tools. The ultimate goal is to improve our understanding of liver cancer and to identify novel strategies that can be exploited therapeutically to improve healthspan and longevity.